Johnson & Johnson Inc and two of its subsidiaries have agreed to pay about $2 billion to the US government and state Medicaid programmes to settle a drug mis-selling case and related matters in which the company is alleged to have improperly promoted the antipsychotic drug Risperdal (risperidone) to elderly patients with dementia.
